The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1547
May 21, 2018
View Complete Issue         Table of Contents 2019 
Trelegy Ellipta - A Three-Drug Inhaler for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Trelegy Ellipta - A Three-Drug Inhaler for COPD
May 21, 2018 (Issue: 1547)
The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta2-agonist (LABA) vilanterol. It is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Trelegy Ellipta - A Three-Drug Inhaler for COPD
Article code: 1547c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.